Transfection News and Research

RSS

SARS-CoV-2 hijacks antiviral factors to promote infection in human lung cells

Now, a new study published in the preprint server bioRxiv in August 2020 shows that under conditions resembling those in vivo, IFNs may promote efficient viral invasion instead.

20 Aug 2020

C-type lectin receptors play a role in SARS-CoV-2 infection

A new study published on the preprint server bioRxiv in August 2020 confirms and extends earlier findings showing that a type of sugar-based receptor on innate immune cells promotes the entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into other cells that carry the viral receptor, angiotensin-converting enzyme 2 (ACE2).

12 Aug 2020

Potential antibody treatment for yellow fever developed in 7 months using Rapid Response Strategy

Yellow fever, an acute viral hemorrhagic disease transmitted by infected mosquitoes, infects about 200,000 people and causes an estimated 30,000 deaths each year.

5 Aug 2020

Stabilized prefusion spike vaccine candidate induces powerful immune response

A new research paper by scientists at Janssen Vaccines & Prevention BV, in the Netherlands and published on the preprint server bioRxiv* is based on the assumption that an effective vaccine against these infections will induce neutralizing antibodies and an immune response favoring Th1 immunity.

3 Aug 2020

Basigin/CD147 discarded as an accessory SARS-CoV-2 binding receptor

By using specialized assays customized to detect specific receptor interactions, researchers from the Wellcome Sanger Institute in Cambridge UK find no evidence for direct binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to a transmembrane glycoprotein known as basigin.

28 Jul 2020

Cat catches coronavirus from owners

Cases of pet animals contracting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported since the coronavirus disease (COVID-19) first emerged. Now, a pet cat has become the first animal in Britain to test positive after contracting the virus from its owners.

28 Jul 2020

Monash University researchers pave way for affordable immunotherapies

Researchers from Monash University’s Institute of Pharmaceutical Sciences are paving the way for accessible and affordable cancer treatment by using powerful nanoscale tools to overcome the high costs and long lead-times associated with one of the world’s newest forms of immunotherapy: CAR-T cell therapy.

22 Jul 2020

Game-Changer: A SARS-CoV-2 serological test for 50-cents per sample!

A recent study published in the preprint server medRxiv in July 2020 shows that this is indeed possible. The development of this inexpensive but reliable and sensitive test could change the face of preventive measures for COVID-19 in low-resource settings.

17 Jul 2020

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Researchers from the National Institutes of Health (NIH) and Cornell University in the U.S. just described several new inhibitors of human coronavirus spike proteins by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Their exciting findings are currently available on the bioRxiv preprint server.

13 Jul 2020

Horizon Discovery introduces Cas9 and dCas9-VPR stable cell lines to simplify and accelerate CRISPR gene editing workflows

Horizon Discovery Group plc, today announced the introduction of its stably expressing Cas9 and dCas9-VPR cell lines to help accelerate gene knockout.

8 Jul 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Scientists examine SARS-CoV-2 cell entry in different species

Researchers in China have demonstrated the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to interact with the host cell receptors of multiple species of animals.

17 Jun 2020

Study explores the role of mi RNAs in anticancer effect exerted by physical activity

Volume 11, Issue 22 of Oncotarget reported that the goal of this study was to explore the involvement of mi RNAs in beneficial effects exerted by physical activity in breast cancer prevention.

3 Jun 2020

A vectored vaccine candidate against SARS-CoV-2

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.

2 Jun 2020